"When you get to the
injectable GLP-1s, you’re talking [about] a $10,000 list price, so there’s a
significant price differential. You would think managed care would have put
some type of management barriers in front of these GLP-1 products, but they
haven’t."
— Jeffrey Casberg, M.S., R.Ph., director of clinical pharmacy at
IPD Analytics, spoke with AIS’s RADAR on Drug Benefits about the latest
happenings in the type 2 diabetes market, with Cigna’s Express Scripts set to
cover Novo Nordisk’s costly glucagon-like peptide-1 receptor (GLP-1) Rybelsus.
No comments:
Post a Comment